Even as a battle royal continues between Teva Pharmaceutical Industries (NYSE: TEVA) and Merck & C0 (NYSEL MRK) over the former’s alleged infringement of the latter’s Januvia (sitagliptin) patent in India, the recent decision of the Indian Patent Office to deny Cipla's patent application for an anti retroviral combination reveals its unbiased nature, reports The Pharma Letter’s India correspondent.
It also brings into play significant amendments brought about by the Patent (Amendment) Rules, 2016, whose main criteria is to fulfil the Indian government’s endeavour and reduce patent application period from the prevailing five-seven years to 18 months by March 2018.
Cipla had filed a patent application (Number 1399) in June 2010 for a pharmaceutical composition comprising ritonavir and darunavir for treating AIDS. The application was filed with 22 claims. An earlier examination report by the Indian Patent Office (IPO) in October 2014 noted all 22 claims lacked novelty and inventive step over the prior art.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze